Log in

Galena Biopharma News Headlines (NYSE:SLS)

$6.14
+0.49 (+8.67 %)
(As of 11/13/2019 07:01 AM ET)
Today's Range
$5.80
Now: $6.14
$5.98
50-Day Range
$0.11
MA: $0.59
$6.14
52-Week Range
$4.79
Now: $6.14
$102.00
Volume638,512 shs
Average Volume229,020 shs
Market Capitalization$27.97 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Galena Biopharma (NYSE SLS) News Headlines

Source:
DateHeadline
 Galena Biopharma, Inc. (NYSE:SLS) Given Average Recommendation of "Buy" by Brokerages Galena Biopharma, Inc. (NYSE:SLS) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 9 at 11:54 AM
SELLAS to Host R&D Investor Event on Galinpepimut-S (GPS) and the Next Generation of Cancer ImmunotherapySELLAS to Host R&D Investor Event on Galinpepimut-S (GPS) and the Next Generation of Cancer Immunotherapy
finance.yahoo.com - November 8 at 8:41 AM
Galena Biopharma, Inc. Stockholders Approve Business Combination with SELLAS Life Sciences Group, Ltd; Board Sets Reverse StockGalena Biopharma, Inc. Stockholders Approve Business Combination with SELLAS Life Sciences Group, Ltd; Board Sets Reverse Stock
www.bloomberg.com - October 3 at 9:34 PM
SELLAS Announces Completion of Enrollment in Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In Situ (DCIS) of the BreastSELLAS Announces Completion of Enrollment in Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In Situ (DCIS) of the Breast
finance.yahoo.com - August 5 at 11:18 AM
Investors Who Bought SELLAS Life Sciences Group (NASDAQ:SLS) Shares A Year Ago Are Now Down 97%Investors Who Bought SELLAS Life Sciences Group (NASDAQ:SLS) Shares A Year Ago Are Now Down 97%
finance.yahoo.com - June 22 at 11:21 AM
SELLAS Life Sciences Announces Closing of $15 Million Public OfferingSELLAS Life Sciences Announces Closing of $15 Million Public Offering
finance.yahoo.com - June 18 at 9:04 PM
SELLAS Announces Immune Response Data in Triple Negative Breast Cancer Patients from Phase 2b Study of Nelipepimut-S (NPS) Plus Trastuzumab Presented at ASCO 2019SELLAS Announces Immune Response Data in Triple Negative Breast Cancer Patients from Phase 2b Study of Nelipepimut-S (NPS) Plus Trastuzumab Presented at ASCO 2019
finance.yahoo.com - June 3 at 11:23 AM
SELLAS Life Sciences Announces Presentation of Final Data Analysis from Phase 2b Study of Nelipepimut-S Plus Trastuzumab at the 2019 ASCO-SITC Clinical Immuno-Oncology MeetingSELLAS Life Sciences Announces Presentation of Final Data Analysis from Phase 2b Study of Nelipepimut-S Plus Trastuzumab at the 2019 ASCO-SITC Clinical Immuno-Oncology Meeting
finance.yahoo.com - March 4 at 8:51 AM
Sellas Reviews Strategic Options To Fund Clinical Development ProgramsSellas Reviews Strategic Options To Fund Clinical Development Programs
finance.yahoo.com - February 26 at 3:59 PM
SELLAS Life Sciences Provides Galinpepimut-S and Nelipepimut-S Program UpdateSELLAS Life Sciences Provides Galinpepimut-S and Nelipepimut-S Program Update
finance.yahoo.com - February 12 at 12:01 PM
SELLAS Life Sciences to Present at the 2019 BIO CEO & Investor ConferenceSELLAS Life Sciences to Present at the 2019 BIO CEO & Investor Conference
finance.yahoo.com - January 31 at 11:14 AM
SELLAS Life Sciences Announces Additional Positive Triple Negative Breast Cancer (TNBC) Subgroup Data from Phase 2b Study of Nelipepimut-S Plus Trastuzumab  at the 2018 San Antonio Breast Cancer SymposiumSELLAS Life Sciences Announces Additional Positive Triple Negative Breast Cancer (TNBC) Subgroup Data from Phase 2b Study of Nelipepimut-S Plus Trastuzumab  at the 2018 San Antonio Breast Cancer Symposium
finance.yahoo.com - December 6 at 3:34 PM
SELLAS Life Sciences Announces Completion of Enrollment in Phase 2 Randomized Controlled Clinical Study of Nelipepimut-S Plus Trastuzumab in High-risk, High-expression HER2 Breast Cancer PatientsSELLAS Life Sciences Announces Completion of Enrollment in Phase 2 Randomized Controlled Clinical Study of Nelipepimut-S Plus Trastuzumab in High-risk, High-expression HER2 Breast Cancer Patients
finance.yahoo.com - November 26 at 10:52 AM
SELLAS Life Sciences Group, Inc. (SLS) CEO Angelos Stergiou on Q3 2018 Results - Earnings Call TranscriptSELLAS Life Sciences Group, Inc. (SLS) CEO Angelos Stergiou on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - November 15 at 3:26 PM
Health Care Stocks Making Moves On Friday; Premier Health Group, Inc. (PHGRF) (PHGI), Sellas Life Sciences, TeladocHealth Care Stocks Making Moves On Friday; Premier Health Group, Inc. (PHGRF) (PHGI), Sellas Life Sciences, Teladoc
finance.yahoo.com - November 9 at 3:27 PM
SELLAS Life Sciences Announces Additional Data Showing Consistent Clinical Effect Across HLA Allele Subgroups in Triple Negative Breast Cancer (TNBC) Patients Treated with Nelipepimut-S Plus Trastuzumab Presented at the Society for Immunotherapy of Cancer (SITC) 2018 Annual MeetingSELLAS Life Sciences Announces Additional Data Showing Consistent Clinical Effect Across HLA Allele Subgroups in Triple Negative Breast Cancer (TNBC) Patients Treated with Nelipepimut-S Plus Trastuzumab Presented at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
finance.yahoo.com - November 9 at 10:40 AM
SELLAS Life Sciences to Provide Third Quarter 2018 Financial Results and Corporate Update on November 15, 2018SELLAS Life Sciences to Provide Third Quarter 2018 Financial Results and Corporate Update on November 15, 2018
finance.yahoo.com - November 8 at 10:28 AM
Big Biotech May Be After These TechnologiesBig Biotech May Be After These Technologies
finance.yahoo.com - November 6 at 3:26 PM
3 Biotechnology & Healthcare Stocks To Watch On Thursday3 Biotechnology & Healthcare Stocks To Watch On Thursday
finance.yahoo.com - November 1 at 3:31 PM
The SELLAS Life Sciences Group Inc (NASDAQ:SLS) Ownership Structure Could Be ImportantThe SELLAS Life Sciences Group Inc (NASDAQ:SLS) Ownership Structure Could Be Important
finance.yahoo.com - October 16 at 3:24 PM
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2018 Financial ResultsSELLAS Life Sciences Provides Business Update and Reports Second Quarter 2018 Financial Results
finance.yahoo.com - August 15 at 8:33 AM
SELLAS Receives Fast Track Designation from FDA for Galinpepimut-S for the Treatment of Patients with Multiple MyelomaSELLAS Receives Fast Track Designation from FDA for Galinpepimut-S for the Treatment of Patients with Multiple Myeloma
finance.yahoo.com - July 20 at 3:19 PM
Sellas Life Sciences Cancer Vaccine Candidate Wins Fast Track Designation In Multiple MyelomaSellas Life Sciences' Cancer Vaccine Candidate Wins Fast Track Designation In Multiple Myeloma
finance.yahoo.com - July 20 at 3:19 PM
SELLAS Life Sciences Announces Closing of $24.2 Million Public OfferingSELLAS Life Sciences Announces Closing of $24.2 Million Public Offering
finance.yahoo.com - July 16 at 3:19 PM
SELLAS Life Sciences Presents Interim Phase 1 Clinical Data of Galinpepimut-S (GPS) in Combination with Nivolumab to Treat Wilms Tumor 1 Positive (WT1+) Ovarian Cancer Patients at ASCO 2018SELLAS Life Sciences Presents Interim Phase 1 Clinical Data of Galinpepimut-S (GPS) in Combination with Nivolumab to Treat Wilms Tumor 1 Positive (WT1+) Ovarian Cancer Patients at ASCO 2018
finance.yahoo.com - June 4 at 3:17 PM
SELLAS Life Sciences Provides Clinical Update on Phase 2b NeuVax™ (nelipepimut-S) Study in Combination with Trastuzumab in HER2 1+/2+ Breast Cancer PatientsSELLAS Life Sciences Provides Clinical Update on Phase 2b NeuVax™ (nelipepimut-S) Study in Combination with Trastuzumab in HER2 1+/2+ Breast Cancer Patients
finance.yahoo.com - June 1 at 3:17 PM
SELLAS Life Sciences to Present Phase 1/2 Clinical Data of Galinpepimut-S (GPS) in Ovarian Cancer at the 2018 American Society of Clinical Oncology (ASCO) Annual MeetingSELLAS Life Sciences to Present Phase 1/2 Clinical Data of Galinpepimut-S (GPS) in Ovarian Cancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - May 17 at 3:16 PM
SELLAS Life Sciences Completes Second Tranche of $10,700,000 Private PlacementSELLAS Life Sciences Completes Second Tranche of $10,700,000 Private Placement
finance.yahoo.com - May 2 at 3:15 PM
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Featured Article: What are Bollinger Bands?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel